Nanobiotix

Nanobiotix is a biotechnology company that uses nanomedicine to develop new radiotherapy techniques for cancer patients. The company is headquartered in Paris, with additional corporate offices in New York and Massachusetts.[1][2]

History

Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo that was incorporated in 2003 [3] and has been primarily funded by leading European venture capital firms (Matignon Technologies, OTC Asset Management, Cap Decisif, Amorcage Rhone-Alpes, CIC Vizille; Masseran Gestion-CGE).

Nanobiotix, founded in 2003 based on research by Laurent Levy at SUNY Buffalo.[4] Between 2007 and 2010, the company focused on the development of the NanoXray research program.

Clinical Trials

NBTXR3 is currently being evaluated in 7 clinical trials around the world, and the development plan will include 16 clinical trials in 8 different types of cancer. In 2019, Nanobiotix launched a clinical collaboration with MD Anderson that includes 9 new Phase I/II clinical trials will be launched in the United States for NBTXR3 in multiple indications, including head and neck, pancreatic, lung, esophageal, and colorectal cancers.[20]

Nanobiotix obtained the first European marketing authorization (CE marking) for Hensify, the commercial name of NBTXR3, for the treatment of locally advanced Soft Tissue Sarcoma.[12]

Soft Tissue Sarcoma

Soft tissue sarcomas (STSs) are a rare type of cancer that develops in different types of soft tissues, including muscles, joint structures, fat, nerves and blood vessels. Although STS can develop at any anatomic site, it occurs in the extremities (arms and legs) in approximately 60% of cases. NBTXR3 completed Phase II/III clinical trials to treat Soft tissue sarcomas in combination with radiotherapy and surgery in April 2020.[8]

Head and Neck Cancer

Chemotherapy in combination with radiation is the standard treatment for locally advanced head and neck cancers in both the United States of America and the European Union. However, such treatment cannot usually be proposed to elderly and frail patients, as they are unable to endure the physical strain inherent in chemotherapy treatment.

NBTXR3 is currently in Phase II/III clinical trials to increase radiotherapy’s efficacy at treating Head and neck cancer. As of 2020, the study is recruiting participants in Taiwan.[21][22]

Hepatocellular carcinoma and liver metastases

According to the World Health Organization, liver cancer is currently the fourth most common cause of cancer death in the world. Surgical resection cannot be performed on many patients, while local and systemic treatment options are few in number and have significant limitations. Radiotherapy has been shown to improve outcomes for these patients, as a direct correlation between higher doses of radiation and increased survival rates have been observed from third party clinical trials. NBTXR3 is currently in Phase I/II clinical trials to increase radiotherapy’s efficacy at treating liver cancer. As of 2020, the study is recruiting participants in France.[23]

Rectal Cancer

Colorectal cancer is the third most common cancer in men and the second most common cancer in women. The five-year survival rate for patients with Rectal cancer is 64.4%, but varies greatly depending on the stage of the cancer and whether the cancer has spread.4NBTXR3 is currently in Phase I/II clinical trials to increase radiotherapy’s efficacy at treating rectal cancer. As of 2020, the study is recruiting participants in Taiwan.[24]

NBTXR3 in combination with immune checkpoint inhibitors

The NANORAY-1100 study is a multicenter, multi-arm, that aims to evaluate the safety, efficacy, and tolerability of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy in Locoregional recurrent (LRR) or recurrent and metastatic (R/M) head and neck squamous-cell carcinoma (HNSCC) and lung and Liver metastasis. It aims to evaluate the hypothesis that the combination of NBTXR3 activated by RT with anti-PD-1 therapy will act synergistically to enhance the therapeutic window of radiation therapy by maximizing the local effect, overcoming radio-resistance, increasing the efficacy of immunotherapy, and potentially producing an abscopal effect for improved distant tumor control. As of 2020, the study is recruiting participants in several states in the United States.[10]

traded as	euronextparis: NANO FR0011341205 CAC Small
foundation	2003
location city	Paris, France
key people	Laurent Levy ( CEO)
industry	Biotechnology
products	NBTXR3 (Hensify®)
operating income	€2.54 million (2019)
assets	€54.9 million (2019)
num employees	110 (2020)
homepage	www.nanobiotix.com

History

Therapeutics

Clinical Trials

Soft Tissue Sarcoma

Head and Neck Cancer

Hepatocellular carcinoma and liver metastases

Rectal Cancer

NBTXR3 in combination with immune checkpoint inhibitors

Corporate structure

Research and development

External links

References